Literature DB >> 8683217

Replication of yellow fever virus in the mouse central nervous system: comparison of neuroadapted and non-neuroadapted virus and partial sequence analysis of the neuroadapted strain.

J J Schlesinger1, S Chapman, A Nestorowicz, C M Rice, T E Ginocchio, T J Chambers.   

Abstract

Serial passage of yellow fever virus (YF17D) in mouse brain enhances neurovirulence, causing a reduction in survival time after intracerebral inoculation of adult mice. To study the biological and genetic basis for this phenomenon, we compared neurovirulence properties of the neuroadapted Porterfield strain (PYF) to a YF17D strain generated from a full-length YF cDNA template (YF5.2iv). Adult mice were infected by olfactory bulb inoculation, which results in widespread distribution of virus throughout the central nervous system. Although PYF and YF5.2iv spread rapidly throughout the neuraxis, maximal titres of PYF in the brain and spinal cord were 1000- to 10,000-fold higher than those of YF5.2iv. Paralysis and death occurred earlier with the PYF strain. Several cDNA clones of the E/NS1 region of the PYF strain were sequenced. Three predicted amino acid changes were consistently observed in the envelope protein of the PYF strain compared to YF5.2iv. Common substitutions were also identified in NS1 and NS2A. The potential contribution of these genetic differences to neurovirulence was evaluated by generating recombinant, intertypic PYF/YF5.2iv viruses. Physical signs of disease and mean spinal cord titres after inoculation of one recombinant were not different from the YF5.2iv parent. Our data indicate that PYF and YF5.2iv differ significantly in their virulence properties, however, common amino acid substitutions in the E/NS1 region of the PYF strain do not determine its enhanced neurovirulence. Other regions of the viral genome may contribute dominant effects on the virulence properties of the PYF strain.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8683217     DOI: 10.1099/0022-1317-77-6-1277

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  20 in total

1.  Attenuation of Murray Valley encephalitis virus by site-directed mutagenesis of the hinge and putative receptor-binding regions of the envelope protein.

Authors:  R J Hurrelbrink; P C McMinn
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

2.  Dynamic viral dissemination in mice infected with yellow fever virus strain 17D.

Authors:  Andrea K Erickson; Julie K Pfeiffer
Journal:  J Virol       Date:  2013-09-11       Impact factor: 5.103

Review 3.  Learning immunology from the yellow fever vaccine: innate immunity to systems vaccinology.

Authors:  Bali Pulendran
Journal:  Nat Rev Immunol       Date:  2009-09-18       Impact factor: 53.106

4.  Yellow fever virus encephalitis: properties of the brain-associated T-cell response during virus clearance in normal and gamma interferon-deficient mice and requirement for CD4+ lymphocytes.

Authors:  T Liu; T J Chambers
Journal:  J Virol       Date:  2001-03       Impact factor: 5.103

5.  Construction, safety, and immunogenicity in nonhuman primates of a chimeric yellow fever-dengue virus tetravalent vaccine.

Authors:  F Guirakhoo; J Arroyo; K V Pugachev; C Miller; Z X Zhang; R Weltzin; K Georgakopoulos; J Catalan; S Ocran; K Soike; M Ratterree; T P Monath
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

6.  Molecular basis for attenuation of neurovirulence of a yellow fever Virus/Japanese encephalitis virus chimera vaccine (ChimeriVax-JE).

Authors:  J Arroyo; F Guirakhoo; S Fenner; Z X Zhang; T P Monath; T J Chambers
Journal:  J Virol       Date:  2001-01       Impact factor: 5.103

7.  Neuroadapted yellow fever virus 17D: genetic and biological characterization of a highly mouse-neurovirulent virus and its infectious molecular clone.

Authors:  T J Chambers; M Nickells
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

8.  Changes in mumps virus gene sequence associated with variability in neurovirulent phenotype.

Authors:  Steven A Rubin; Georgios Amexis; Mikhail Pletnikov; Zongqi Li; Jacqueline Vanderzanden; Jeremy Mauldin; Christian Sauder; Tahir Malik; Konstantin Chumakov; Kathryn M Carbone
Journal:  J Virol       Date:  2003-11       Impact factor: 5.103

9.  The development of therapeutic antibodies that neutralize homologous and heterologous genotypes of dengue virus type 1.

Authors:  Bimmi Shrestha; James D Brien; Soila Sukupolvi-Petty; S Kyle Austin; Melissa A Edeling; Taekyung Kim; Katie M O'Brien; Christopher A Nelson; Syd Johnson; Daved H Fremont; Michael S Diamond
Journal:  PLoS Pathog       Date:  2010-04-01       Impact factor: 6.823

10.  A functional epitope determinant on domain III of the Japanese encephalitis virus envelope protein interacted with neutralizing-antibody combining sites.

Authors:  Cheng-Wen Lin; Suh-Chin Wu
Journal:  J Virol       Date:  2003-02       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.